![](/img/cover-not-exists.png)
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer
Scagliotti, Giorgio, Kang, Jin Hyoung, Smith, David, Rosenberg, Richard, Park, Keunchil, Kim, Sang-We, Su, Wu-Chou, Boyd, Thomas E., Richards, Donald A., Novello, Silvia, Hynes, Scott M., Myrand, ScotVolume:
34
Language:
english
Journal:
Investigational New Drugs
DOI:
10.1007/s10637-016-0368-1
Date:
October, 2016
File:
PDF, 771 KB
english, 2016